

SCOPE: ALS, CCT,	
MEDICATION:	ALBUTEROL (Ventolin)
INTERVENTION:	<p><u>Classification:</u> Beta-2 Agonist</p> <p><u>Actions:</u> Relaxes bronchial smooth muscle by action on beta₂-receptors</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Hypersensitivity • Tocolytic use in patients at risk of premature labor or threatened abortion <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Monitor for paradoxical bronchospasm that may occur with administration, differentiate from inadequate response to treatment • Use caution in patients with (may cause): <ul style="list-style-type: none"> ○ Cardiovascular disease (tachycardia, arrhythmia) ○ Diabetes (hyperglycemia) ○ Glaucoma (elevated intraocular pressure) ○ Hyperthyroidism (thyroid stimulation) ○ Hypokalemia (decreased serum potassium) ○ Renal Impairment ○ Seizures (CNS stimulus/excitation) <p><u>Concentration:</u></p> <ul style="list-style-type: none"> • Unit dose Adult/Pediatric: 2.5 mg in 3ml NS • Unit dose Neonatal: 1.25 mg in 3 ml NS • Continuous administration: refer to product insert for mixing instructions <p><u>Dosage:</u></p> <ol style="list-style-type: none"> I. <u>Dyspnea related to:</u> <ol style="list-style-type: none"> a. Reactive airway disease (Asthma, COPD)/Wheezing <ol style="list-style-type: none"> i. COPD Exacerbation <ol style="list-style-type: none"> 1. Continuous administration: 20 mg/hr ii. Acute Asthma <ol style="list-style-type: none"> 1. Adult/Pediatric (SVN): <ol style="list-style-type: none"> a. 2.5mg unit dose in 3ml NS over 5-10 mins (x2 q 10 mins) 2. Adult/Pediatric (Continuous administration): <ol style="list-style-type: none"> a. 5-10 kg: 10 mg/hr b. 10-20 kg: 15 mg/hr c. >20 kg: 20 mg/hr b. Bronchiolitis <ol style="list-style-type: none"> i. Adult/Pediatric: <ol style="list-style-type: none"> 1. Unit dose via SVN every 10 minutes x 2, may for total of 2 doses if responsive ii. Neonatal: <ol style="list-style-type: none"> 1. 0.5 ml of 2.5 mg (1.25mg) unit dose in 3ml NS over 5-10 min x2 every 10 min II. <u>Hyperkalemia:</u> <ol style="list-style-type: none"> a. Adult: 1-2 unit doses via SVN

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

FOR OFFICE USE ONLY	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 2

PROTOCOL

	<p><u>Onset of Action:</u> < 15 minutes. Peak: 30 minutes – 2 hours</p> <p><u>Duration:</u> 2 - 6 hours</p> <p><u>Adverse Effects:</u> Excitement, tremors, tachycardia, arrhythmia, diaphoresis, nausea/vomiting, cramping</p> <p><u>Special Considerations:</u></p> <p>I. N/A</p>
--	--